ENTRADA THERAPEUTICS INC. - COMMON STOCK

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

03 Jun 2025 04:00:00 By Nasdaq GlobeNewswire

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 Jun 2025 13:30:00 By Nasdaq GlobeNewswire

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

28 May 2025 04:00:00 By Nasdaq GlobeNewswire

Entrada Therapeutics Reports First Quarter 2025 Financial Results

08 May 2025 04:00:00 By Nasdaq GlobeNewswire

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

24 Mar 2025 04:00:00 By Nasdaq GlobeNewswire

Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

27 Feb 2025 04:00:00 By Nasdaq GlobeNewswire

Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44

24 Feb 2025 04:00:00 By Nasdaq GlobeNewswire

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy

03 Feb 2025 04:00:00 By Nasdaq GlobeNewswire

Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

18 Dec 2024 04:00:00 By Nasdaq GlobeNewswire

Entrada Therapeutics Reports Third Quarter 2024 Financial Results

05 Nov 2024 04:00:00 By Nasdaq GlobeNewswire

Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society

09 Oct 2024 04:00:00 By Nasdaq GlobeNewswire

Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development

24 Sep 2024 04:00:00 By Nasdaq GlobeNewswire

Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program

06 Sep 2024 04:00:00 By Nasdaq GlobeNewswire

Entrada Therapeutics Reports Second Quarter 2024 Financial Results

13 Aug 2024 04:00:00 By Nasdaq GlobeNewswire

Entrada Therapeutics Announces $100 Million Registered Direct Offering

24 Jun 2024 04:15:28 By Nasdaq GlobeNewswire

Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy

24 Jun 2024 03:00:00 By Nasdaq GlobeNewswire

Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference

03 Jun 2024 04:00:00 By Nasdaq GlobeNewswire

Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

16 May 2024 04:00:00 By Nasdaq GlobeNewswire

Entrada Therapeutics Reports First Quarter 2024 Financial Results

07 May 2024 04:00:01 By Nasdaq GlobeNewswire

Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

13 Mar 2024 04:00:00 By Nasdaq GlobeNewswire